L9LS-R21 Interaction

NCT07208760 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped After careful review of R21 interaction data that recently became available from a previous L9LS infant study, the study team has made the decision to not move forward with this protocol.

Conditions

Malaria

Interventions

DRUG: Single dose of 1800 mg L9LS SC (12mL)
OTHER: Placebo 12 mL SC
DRUG: Single dose of 225 mg L9LS SC (1.5mL)
OTHER: Placebo 1.5 mL SC

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]